Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookGuidelines to Antiretroviral Drug Therapy in Kenya (WHO; 2001; 78 pages)
View the documentFOREWORD
View the documentACKNOWLEDGMENT
close this folderCHAPTER ONE: INITIATING ANTIRETROVIRAL THERAPY
View the document1.1 Introduction
View the document1.2 Guidelines to making a diagnosis of HIV infection
View the document1.3 Laboratory Diagnosis of HIV infection
View the document1.4 Goals of therapy
View the document1.5 When to start therapy
View the document1.6 Risks and benefits of delayed initiation of therapy and of early therapy in the Asymptomatic HIV-Infected Patient
View the document1.7 Antiretroviral profile
View the document1.8 What drug combination to start with?
Open this folder and view contentsCHAPTER TWO: MONITORING AND CHANGING THERAPY
Open this folder and view contentsCHAPTER THREE: PHARMACOTHERAPEUTICS OF ARVS
Open this folder and view contentsCHAPTER FOUR: GUIDELINES FOR THE USE OF ANTIRETROVIRAL DRUGS IN PAEDIATRIC HIV INFECTION
Open this folder and view contentsCHAPTER FIVE: MANAGEMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PREGNANT WOMEN AND PREVENTION OF MOTHER TO CHILD TRANSMISSION (MTCT) OF HIV
Open this folder and view contentsCHAPTER SIX: SPECIAL CONSIDERATIONS
Open this folder and view contentsCHAPTER SEVEN: WHEN TO STOP TREATMENT (INTERRUPTIONS)
Open this folder and view contentsCHAPTER EIGHT: GUIDELINES FOR POST EXPOSURE PROPHYLAXIS
View the documentCHAPTER NINE: ACCESS TO DRUGS IN KENYA
Open this folder and view contentsAPPENDICES
View the documentBACK COVER
 

1.4 Goals of therapy

The primary goals of antiretroviral therapy are maximal and durable suppression of plasma viral load, preservation and/or restoration of immunologic function, improvement of quality of life and reduction of HIV related morbidity and mortality.

• Clinical benefit has been demonstrated in controlled trials only for patients with CD4+T cells <200/mm3. However, most experts would offer therapy at a CD4+T cell threshold <350/mm. All decisions to initiate therapy should be based on prognosis for disease-free survival in the absence of treatment, as determined by the CD4+ cell count and level of plasma HIV RNA shown in Table 5, the potential benefits and risks of therapy shown in Table 4, and the willingness of the patient to accept therapy.


Goals of HIV Therapy and Tools to achieve them Goals of therapy

• Maximal and durable suppression of Viral load.
• Restoration and/or preservation of immunologic function.
• Improvement of quality of life.
• Reduction of HIV related morbidity and mortality.


Tools to Achieve Goals of Therapy

• Maximum adherence to the antiretroviral regimen
• Rational sequencing of drugs
• Preserving future treatment options.
• Use of resistance testing in selected Clinical settings where possible.

to previous sectionto next section

Please provide your feedback English  |  French